2021-RD-Philip-Sharp
November 18, 2021
Please login to view this video.
-
Video details
Among biotechnology’s early successes were the introduction of interferons and other proteins as therapeutic agents. Over the next twenty years, larger macromolecules such as monoclonal antibodies were developed, changing the outcome of many previously untreatable diseases. Oligonucleotides are an emerging class of therapeutic agents with comparable promise for the benefit of patients. The history and future promise of anti-sense oligonucleotides, siRNA and other RNAs will be discussed.
Please login to view this video.
-
Video details
Among biotechnology’s early successes were the introduction of interferons and other proteins as therapeutic agents. Over the next twenty years, larger macromolecules such as monoclonal antibodies were developed, changing the outcome of many previously untreatable diseases. Oligonucleotides are an emerging class of therapeutic agents with comparable promise for the benefit of patients. The history and future promise of anti-sense oligonucleotides, siRNA and other RNAs will be discussed.
